ALTEOGEN Inc. Overview
Alteogen is a Daejeon-based biopharmaceutical platform company. It is one of only two companies in the world that has commercialised a recombinant human hyaluronidase able to turn intravenous (IV) biologics into subcutaneous (SC) injections. The other is Halozyme of the US. Alteogen's enzyme, ALT-B4 (berahyaluronidase alfa), comes from its Hybrozyme™ platform. It is co-formulated in Merck & Co.'s Keytruda Qlex™ / Keytruda SC, the first SC PD-1 inhibitor, which the FDA approved in September 2025.
Alteogen earns upfront payments, milestones, ALT-B4 supply revenue and royalties from ten global pharma licensees: MSD, Sanofi, Intas, Sandoz, Daiichi Sankyo, AstraZeneca, GSK/Tesaro, Biogen, an undisclosed partner and Novartis. Disclosed headline deal values total roughly KRW 16 trillion. The company also has biosimilars (Eylea biosimilar Eyluxvi®/Eyzenpi®, and a Herceptin biosimilar sold in China), a standalone hyaluronidase (Tergase®), ADC and long-acting platforms, and an early obesity candidate. Alteogen turned profitable in 2024. In 2025 it reported record revenue of KRW 215.9bn with a 49.5% operating margin.
Company self-description
In its press-release boilerplate and filings, Alteogen describes itself as a biopharmaceutical company that specialises in platform technologies for next-generation biologics. It names four areas:
-
Hybrozyme™, its human hyaluronidase platform for IV-to-SC conversion
-
NexP™ fusion technology, for long-acting biobetters
-
NexMab™, its antibody-drug conjugate (ADC) technology
-
Antibody biosimilars, developed in-house and with partners
The FY2025 earnings disclosure (27 February 2026) gave three reasons for record results. First, it recognised more revenue tied to Hybrozyme, including milestones from Keytruda SC's FDA and EMA approvals and the AstraZeneca upfront. Second, ALT-B4 supply sales grew. Third, royalties from the Herceptin biosimilar Anqutuo (安曲妥) in China increased.
Independent characterisation
Economically, Alteogen is a B2B enabling-technology licensor and specialty API supplier, with a small but growing product business attached.
Licensing. Partners pay Alteogen to co-formulate ALT-B4 with their own monoclonal antibodies, ADCs or other biologics. The goal is to deliver a large-volume SC dose in minutes instead of a 30–60 minute IV infusion. Merck's Keytruda Qlex is described as being given in about one minute. The licensor model has very high incremental margins: FY2025 gross margin was 76.7% and FY2025 operating margin was 49.5%.
Supply. Alteogen is contractually responsible for clinical and commercial supply of ALT-B4 to most licensees, including MSD, AstraZeneca, Tesaro, Intas and Sandoz. It currently uses outside contract manufacturers (CMOs), some overseas. A KRW 253.2bn in-house drug substance / drug product plant in Daejeon is due by September 2028.
Products. Alteogen sells Tergase® (recombinant human hyaluronidase) in Korea. It markets the aflibercept biosimilar ALT-L9 (approved in the EU as Eyluxvi® in September 2025 and in Korea as Eyzenpi®/아이젠피 in May 2026). It receives royalties on the trastuzumab biosimilar ALT-L2, which Qilu Pharmaceutical sells in China.
Pipeline optionality. Earlier-stage programmes include NexMab ADCs (ALT-P7), NexP long-acting proteins (ALT-P1, a long-acting growth hormone), and a new long-acting conjugate platform. The lead candidate on that platform is ALT-M5, a once-monthly incretin fusion protein for obesity.
Revenue model mix
| Revenue stream | Nature | Visibility |
|---|---|---|
| Technical services / licensing (ALT-B4) | Upfronts, option fees, development and regulatory milestones, sales milestones, royalties | Upfronts are lumpy. Sales milestones and royalties now scale with Keytruda Qlex sales. |
| ALT-B4 supply | Product revenue from enzyme supplied to licensees for clinical and commercial use | Grows with partner volume |
| Merchandise and products | Tergase®, ALT-L9 and other goods sold through the former Alteogen Healthcare / Alteogen Biologics channels | Small so far |
| Other technical services | Royalties (e.g., Anqutuo in China) and service contracts | Recurring, modest |
A Butler summary of the H1 2026 semi-annual report gives the Q2 2026 revenue mix as about 88% ALT-B4 technical services, about 9% merchandise and about 3% other technical services. For FY2024, the Korea IR Council reported technical services of KRW 78.1bn (including KRW 2.4bn of other items), merchandise sales of KRW 10.0bn and product sales of KRW 14.7bn, for total revenue of KRW 102.9bn.
Value-chain position, customers and end-markets
Value-chain position: Alteogen sits upstream as the technology owner and API (enzyme) supplier. Partners run late-stage clinical development, regulatory filings and commercialisation. Alteogen manages enzyme regulatory files, CMC (chemistry, manufacturing and controls) and supply.
Customer types: - Global innovator pharma: MSD, Sanofi, AstraZeneca/MedImmune, Daiichi Sankyo, GSK/Tesaro, Biogen, Novartis and one undisclosed company
-
Biosimilar and generic majors: Sandoz, Intas
-
Regional partners: Qilu (China), Cristália (Brazil), Kissei (Japan, ALT-L9)
-
Korean hospitals and clinics for Tergase
End-markets: - Oncology: immuno-oncology (PD-1) and ADCs, which make up most of the value today
-
Immunology and neurology: Biogen (felzartamab and others)
-
Multiple modalities under the Novartis options
-
Ophthalmology: anti-VEGF biosimilar
-
Breast and gastric cancer biosimilars
-
Aesthetic and pain-adjunct hyaluronidase: Tergase
-
Prospectively, obesity (ALT-M5)
Strategy
Stated strategic themes (paraphrased from company statements, 2025–2026)
-
Scale the Hybrozyme franchise. Add licensees and more products per licensee. The goal is six or more additional commercial products by 2030, on top of the three commercial products the company counted in January 2026: Keytruda SC, Anqutuo and Tergase/ALT-L9.
-
Move from licensing income to sales-based income. Turn Keytruda SC sales milestones (up to US$1bn) and later royalties into recurring revenue. The CEO said in H1 2026 that partner product sales had begun generating income.
-
Diversify beyond one platform. The CEO stated in October 2026 that the company should not depend on a single platform. KRW 150bn of the October 2026 raise is earmarked for acquiring products and technologies and for R&D. New modalities include RNA (Daishin, August 2026) and the long-acting conjugate platform (ALT-M5).
-
Bring manufacturing in-house with the Daejeon DS/DP plant, for supply security and margin capture. This also responds to supply-chain politics such as the US BIOSECURE Act, which the founder cited in February 2025.
-
Governance and capital-markets maturation: a professional CEO, a majority-independent board, an audit committee, an ESG programme, the first dividend, and bonus issues. The KOSPI transfer has been deferred, not abandoned.
Initiatives in the last 24 months
| Date | Initiative | Detail / target |
|---|---|---|
| Feb 2025 | RCPS raise | KRW 155bn (434,848 shares at KRW 356,433) for a plant, HQ relocation and operations. NH, DB, Kiwoom, KB funds and others subscribed. |
| 2,025 | Sought external platforms and M&A | Founder said "bold investment for the next 10 years". A possible JV with Orion for manufacturing was floated in press (February 2025) and is unconfirmed. |
| Sep 2025 | KOSPI transfer process | Korea Investment & Securities appointed as lead manager (29 September 2025). |
| Dec 2025 | Leadership transition | Board-centred management model |
| Dec 2025 | ALT-B4 option agreement | Undisclosed partner; final decision due in 2026 |
| Jan 2026 | Strategy communication after the royalty sell-off | Royalty term to early 2043. Two or more companies in due diligence. Target of 6+ products by 2030. |
| Feb 2026 | Shareholder returns | First cash dividend, KRW 371 per share (about KRW 20bn), paid from tax-exempt capital reserves |
| Mar–Apr 2026 | "First year of ESG management" | Audit committee; majority-independent board; Logblack ESG data platform (16 April 2026); first GRI-based sustainability report planned for 2026 |
| Jul 2026 | Capital-markets reset | KOSPI transfer suspended; 30% bonus issue |
| Aug 2026 | Manufacturing | KRW 253.2bn Daejeon plant (55.7% of FY2025 equity) |
| Sep 2026 | New platform | Long-acting conjugate PCT; ALT-M5 data at ObesityWeek, November 2026 |
| Oct 2026 | Growth capital | KRW 200bn from SkyAlt (CPS and RCPS, KRW 100bn each): KRW 150bn for new products, technology and R&D; KRW 50bn for the plant |
| Oct 2026 | Simplification | Merger of Alteogen Biologics into the parent to bring development, regulatory and commercial capabilities in-house |
Guidance and medium-term targets
Alteogen does not publish formal quantitative financial guidance. Its qualitative outlook is for continued revenue from milestones and royalties as licenses mature (Q1/Q2 2026 materials). Brokers forecast 2026 operating profit above KRW 300bn (Kormedi, citing the securities industry, July 2026). This compares with H1 2026 operating profit of KRW 73.5bn, which implies a heavy H2 skew that depends on sales milestones and option fees.
Products & Services
Hybrozyme™ platform / ALT-B4 (berahyaluronidase alfa)
| Attribute | Detail |
|---|---|
| Description | A recombinant human hyaluronidase (a PH20 variant) engineered by domain swapping for better thermal stability and activity. It temporarily breaks down hyaluronan in the subcutaneous extracellular matrix so that large-volume biologics can be given by SC injection. |
| INN | Berahyaluronidase alfa (US suffix for the Merck product: -pmph) |
| Key IP | US composition patent family expected to run to about 2043. Merck royalties run until early 2043 (company statement, 21 January 2026). European patent granted 10 June 2026. Halozyme's IPR against Alteogen's manufacturing-process patent US 12,221,638 was denied institution. |
| Target customers | Global innovator pharma (IO, ADCs, immunology, neurology) and biosimilar developers seeking differentiated SC biosimilars |
| Pricing model | Upfront or option fees, development, regulatory and sales milestones, tiered royalties, and supply revenue. Disclosed or reported royalty data points: about 2% for Keytruda SC (per Merck's Q3 2025 10-Q as reported by Korean media); "mid-single-digit" for Biogen combination products (Biogen 10-Q); 10% or more for the Sandoz and Intas biosimilar deals (company comments, 2022). |
| Commercial status | First commercial product: Keytruda Qlex™ / Keytruda SC (Merck). Approved in the US (September 2025), EU (November 2025) and Japan (September 2026); 41 countries in total per October 2026 reports. Sales: US$40m in Q4 2025, US$128m in Q1 2026, US$463m in Q2 2026 (Merck). |
| Recent technical data | May 2026: ALT-B4 combined with a Becton Dickinson delivery device in animal studies (PDA Miniverse 2026) cut administration time and sped dispersion. June 2026: ALT-B4 co-administered with ADCs (World ADC) suggested improved skin-toxicity and safety markers. |
| Partner | Product / scope | Stage (latest known) |
|---|---|---|
| MSD (Merck & Co.) | Keytruda (pembrolizumab) SC, exclusive. Non-exclusive rights for other MSD targets remain under the 2020 agreement. | Marketed (Keytruda Qlex / Keytruda SC) |
| Sanofi | 2019 license (disclosed in Q2 2026); targets undisclosed | — |
| Intas | Two products (biosimilar SC) | Pivotal Phase 1 of a biosimilar SC started (company IR, February 2025) |
| Sandoz | Joint development of a new hyaluronidase for SC biosimilars (since July 2024) | Development |
| Daiichi Sankyo | Enhertu (trastuzumab deruxtecan) SC | Phase 1 started September 2025 |
| AstraZeneca (MedImmune UK and US) | SC formulations of several oncology assets (two agreements) | Clinical trials in progress (CEO, February 2026); assets undisclosed |
| GSK / Tesaro | Dostarlimab (Jemperli) SC | Development |
| Biogen | Two biologics, one being felzartamab (Biogen 10-Q), plus an option on a third | Development |
| Undisclosed global pharma | One SC biologic, worldwide (5 August 2026) | Development |
| Novartis | Options on multiple products and modalities | Option stage |
Tergase® (ALT-BB4) — standalone recombinant human hyaluronidase
Description: A high-purity recombinant human hyaluronidase. It is positioned against animal-derived (bovine or ovine) products and against Halozyme's Hylenex, citing lower injection-site reaction rates (company and Shinhan comparisons).
Approval: Korean MFDS, July 2024.
Indications: Adjunct for dispersion and absorption of injected drugs, and relief of pain and oedema (aesthetic and procedural use).
Channel: Originally Alteogen Healthcare, then Alteogen Biologics after the 2025 merger. Clinic-channel co-promotion with PharmaResearch. Hospital formulary listings went past 40 general hospitals early in launch, with a target of more than 100.
Commercial traction: Korean press (Dealsite, 2026) describes uptake as underwhelming. Revenue is not separately disclosed.
Biosimilars
| Product | Reference / target | Status | Commercial model |
|---|---|---|---|
| ALT-L9: Eyluxvi® (EU), Eyzenpi® / 아이젠피 (Korea) | Eylea (aflibercept); wAMD, RVO macular oedema, DME, myopic CNV | EC approval 17 September 2025 (CHMP positive opinion July 2025). Korean MFDS approval May 2026. Saudi Arabia approval Q2 2026. Launch preparation under way. | In-house and Alteogen Biologics. Kissei historically partnered for Japan. Future in-house manufacturing at the Daejeon plant. |
| ALT-L2: Anqutuo / 安曲妥 (China) | Herceptin (trastuzumab), IV | Approved and launched in China (2024) by Qilu | Royalty on net sales (described as industry-average, about 10 years). Qilu and Alteogen are discussing ex-China expansion. Cristália holds Brazil rights. |
| ALT-LS2 | Trastuzumab SC (biosimilar plus ALT-B4) | Development (historical pipeline) | — |
NexMab™ ADC platform
ALT-P7: A HER2-targeted ADC for breast and gastric cancer built on site-specific conjugation. It has reached Phase 1 (historical disclosures).
Strategic use: The conjugation know-how now underpins the long-acting conjugate platform. ALT-B4 plus ADC co-administration is being studied (World ADC, June 2026).
NexP™ long-acting fusion platform
ALT-P1: A long-acting human growth hormone (Phase 2 / IIa; Cristália in Brazil received Phase 2 IND approval per February 2025 IR).
Long-acting conjugate platform and ALT-M5 (obesity)
Platform: It extends the site-specific antibody conjugation technology to combine several active molecules into one conjugate and extend half-life. The PCT filing was completed in September 2026.
ALT-M5: A once-monthly incretin fusion protein. Animal studies suggest monthly dosing is feasible and that weight regain after stopping is suppressed. Data are due at ObesityWeek 2026 (Washington, D.C., 14–17 November 2026). The asset is preclinical, and pricing and partnering are not disclosed.
Manufacturing / CDMO capability (planned)
Daejeon Dungok plant: KRW 253.2bn over about 3 years for drug substance and drug product manufacturing, completion by 30 September 2028. Planned products are ALT-B4 and ALT-L9.
-
Former CEO Park said in August 2025 that the Korean site would supply Keytruda SC enzyme for all markets except the US, with the US supplied through a local CMO.
-
Brokers speculate about future third-party CDMO revenue. This is not a company commitment.
Financial Detail
Group Entities
| Entity | Ownership | Role | Status |
|---|---|---|---|
ALTEOGEN Inc. (parent) | Listed | R&D, licensing, ALT-B4 regulatory and supply management, corporate | Operating |
Alteogen Biologics Inc. (formerly Altos Biologics) | 62.89% (end-2025; book value about KRW 89bn) | ALT-L9 global clinical development and regulatory work. Biosimilar sales and marketing, inherited from the absorbed Alteogen Healthcare. CEO Ji Hee-jung. | Being merged into the parent (announced 6 October 2026; ratio 1:0.1679581; 600,477 new parent shares; completion targeted for December 2026). A planned standalone IPO was dropped in July 2026 amid "duplicate listing" rules. |
Alteogen Healthcare | 51.5% at end-2024 | Tergase and growth-hormone/adhesion-barrier marketing | Absorbed by Altos Biologics in April 2025 |
Revenue type (KRW Bn)
| Revenue type (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Technical services (licensing / ALT-B4, incl. other) | — | — | — | 78.1 | — |
Merchandise sales | — | — | — | 10.0 | — |
Product sales | — | — | — | 14.7 | — |
Total revenue | 38.7 | 28.8 | 96.5 | 102.9 | 215.9 |
Income Statement and Per-Share Data
| Metric (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 38.7 | 28.8 | 96.5 | 102.9 | 215.9 |
Gross profit | — | — | — | 64.1 | 165.6 |
Operating income | -15.2 | -29.4 | -9.7 | 25.4 | 106.9 |
Net income | -11.6 | -10.1 | -3.6 | 60.7 | 144.3 |
Dividend per share (KRW) | 0 | 0 | 0 | 0 | 371 |
Margin Analysis (%)
| Ratio (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | — | — | — | 62.3 | 76.7 |
Operating margin | -39.3 | -102.1 | -10.1 | 24.7 | 49.5 |
Net margin | -30.0 | -35.1 | -3.7 | 59.0 | 66.8 |
Revenue growth YoY | — | -25.6 | 235.1 | 6.6 | 109.9 |
Income Statement
| Metric (KRW Bn) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Revenue | 83.7 | 18.6 | 49.0 | 64.5 | 71.6 | 68.8 |
Operating income | 60.9 | -0.4 | 26.7 | 19.6 | 39.3 | 34.1 |
Net income | 83.0 | -34.3 | 22.0 | 73.6 | 71.3 | 30.0 |
Balance Sheet
| Metric (KRW Bn) | FY2025 |
|---|---|
Total assets | 697.9 |
Total liabilities | 244.3 |
Total equity | 453.6 |
Cash Flow
| Metric (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow | -9.5 | -17.9 | -7.8 | 53.0 | 124.1 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%) (FY2023–FY2025)
| Ratio | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ROE (%) | — | — | 29.5 |
ROA (%, on year-end assets) | — | — | 20.7 |
Total liabilities / equity (%) | — | — | 53.9 |
Current ratio, separate basis (%) | 824.5 | 729.6 | 256.3 |
Revenue source
| Revenue source | Counterparty domicile | End-market geography | Direction |
|---|---|---|---|
MSD milestones and royalties (Keytruda SC) | US (MSD International / Merck & Co.) | US-led (October 2025 launch), Japan (approved September 2026), EU (constrained in Germany plus eight countries by injunctions) | Fastest growing |
AstraZeneca / MedImmune upfronts and milestones | UK and US | Global | Event-driven |
Daiichi Sankyo | Japan | Global | Development milestones |
GSK / Tesaro, Biogen, Novartis, undisclosed partner | US / Switzerland / undisclosed | Global | Upfronts in 2026, milestones later |
Sandoz, Intas | Switzerland, India | Global biosimilar markets | Development |
Anqutuo royalties (Qilu) | China | China | Growing (cited in FY2025 results) |
Tergase and ALT-L9 product sales | Korea / EU / Saudi Arabia | Korea and Europe | Early stage |
Share Price & Returns
| Horizon | Performance | Basis |
|---|---|---|
1-year | About –25% to –35% | KRW 458,000 on 30 September 2025 (pre-bonus) is about KRW 352,300 adjusted, versus about KRW 250,000 in late September / early October 2026 |
3-year | Strongly positive, roughly +450% to +700% (not precisely verified) | Pre-bonus trading of about KRW 37,000–60,000 in H2 2023 versus about KRW 325,000 on a pre-bonus-equivalent basis today |
Market Valuation
| Metric (KRW trillion) | Dec 2022 | Nov 2024 | Dec 2025 | Jan 2026 | Oct 2026 |
|---|---|---|---|---|---|
Market capitalisation | 2.03 | 17.6 | 24.3 | 25.9 | 17.4 |
Valuation Multiples
| Multiple | Alteogen | Comment |
|---|---|---|
P/E (TTM) | About 88–90x | Butler shows 90.0x; derived TTM net income about KRW 196.9bn |
Forward P/E (fPER) | About 57x | Butler consensus |
EV/Sales (TTM) | About 68x | Assumes EV close to market cap (net cash not fully disclosed) |
EV/EBITDA (TTM) | About 130–145x | EBITDA close to operating income (about KRW 120bn TTM) |
P/B | About 32x | Butler |
Analyst Ratings & Targets
| Broker | Rating | Target (KRW) | Date | Basis |
|---|---|---|---|---|
Shinhan Investment | Buy | 540,000 | Sep 2026 | Novartis deal; up to about 10 compounds |
Daishin Securities | Buy | 450,000 (from 410,000) | 3 Sep 2026 | rNPV-DCF; fair value KRW 31.4tn; 2 new deals a year assumed |
Daol Investment | Not rated | — | 3 Sep 2026 | Platform scalability |
Kiwoom Securities | Commentary | — | 22 Jan 2026 | Flagged the 2% royalty as an "uncomfortable truth" |
Consensus | — | About 438,000 (9 brokers, Butler) or 458,000 (Investing.com) | Sep–Oct 2026 | Targets are mostly post-bonus; some may not be fully adjusted |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share (KRW) | 0 | 0 | 0 | 0 | 371 |
Dividend total (KRW Bn) | 0 | 0 | 0 | 0 | 20 |
Analyst Conclusions
Management guidance and consensus
Alteogen gives no quantitative guidance. Management expects continued milestone and royalty inflows, more licensing deals (two or more companies were in due diligence as of January 2026, and three deals followed), six or more additional commercial products by 2030, and diversification through the KRW 200bn growth capital. The sell-side 2026 operating profit expectation is above KRW 300bn. Against H1 2026 operating profit of KRW 73.5bn, that requires a very strong H2 from Keytruda SC sales milestones, Novartis option economics and the August 2026 deal upfront. Risk to consensus: elevated.
Bull case
-
The Keytruda SC volume ramp outruns the low royalty. Sales of US$463m in Q2 2026 rose about 262% quarter on quarter. If the 30–40% conversion Merck targets is reached on a franchise of about US$30–35bn, up to US$1bn of sales milestones could arrive by about 2028–2029, followed by royalties to 2043.
-
Partner flywheel. Four deals in 2026, including Novartis' multi-product structure worth up to US$3.2bn. Several partner programmes are already in the clinic: Enhertu SC Phase 1 and AstraZeneca assets. This builds a pipeline of royalty-bearing products for 2028–2032.
-
IP momentum in key forums. PTAB invalidations, the UK revocation, the denied IPR on Alteogen's process patent and the European ALT-B4 patent grant support Alteogen's long-term freedom to operate in the US, the largest market.
Bear case
-
Europe is now a meaningful hole. Keytruda SC is enjoined in Germany plus eight countries. If the US D.N.J. case goes against Merck, a settlement or license fee could dilute Alteogen's economics or delay US sales milestones.
-
Economics below perception. About 2% royalties, confidential upfronts and an option-heavy Novartis structure mean headline deal values materially overstate risk-adjusted cash flows. The market's reactions in January and September 2026 show these gaps recur.
-
Valuation. About 88x TTM P/E and about 32x book leave little margin for error while capex (KRW 253bn) and diversification spending (KRW 150bn) rise and preferred-share dilution builds.
Catalysts and monitorables (next 12 months)
13 Nov 2026: Q3 2026 results (recognition of the first sales milestone; revenue mix).
14–17 Nov 2026: ALT-M5 obesity data at ObesityWeek.
19 Nov 2026: Munich appeal hearing on the German preliminary injunction.
Q4 2026: Merck's response to the Hague judgment (appeal or stay); the D.N.J. ruling after the 31 July 2026 argument.
Dec 2026: Completion of the Alteogen Biologics merger; plant groundbreaking.
Rolling: Further Keytruda SC sales milestones (watch Merck quarterly SC sales). Novartis option exercises. Additional licenses. Enhertu SC and AstraZeneca clinical updates. Eyluxvi European launch. Possible return to the KOSPI transfer agenda.
Concluding analyst verdict
Alteogen has made the hard transition from a platform promise to commercial proof. Its enzyme sits inside Keytruda Qlex, now growing by hundreds of millions of dollars a quarter. Ten global pharma companies have licensed ALT-B4, and the 2025 accounts show what the model can deliver: KRW 215.9bn of revenue, a 49.5% operating margin and KRW 124bn of operating cash flow from a workforce of under 200. Recent PTAB, UK and patent-office outcomes favour the company's US position and IP durability. The 2026 run of four licenses, especially Novartis' multi-product option, argues that big pharma views ALT-B4 as a credible second source to Halozyme's ENHANZE.
Three facts temper the thesis. First, the Merck royalty is low, at about 2%, so the value of the flagship asset lies largely in up to US$1bn of sales milestones and in volume, not rate. Second, Halozyme's MDASE estate has now won injunctions in nine European countries, and the US merits case is unresolved. A settlement between Merck and Halozyme, which we see as a plausible end-state, could carry costs that flow through to Alteogen's economics, depending on contractual indemnities that are not publicly disclosed. Third, the company is reinvesting heavily in a plant and in diversification at a time when its earnings remain episodic. It has also chosen confidentiality on most deal terms, which repeatedly produces sharp gaps between expectations and reality.
Net assessment: Alteogen is a strategically important, profitable, IP-rich platform whose medium-term cash generation is visible but whose valuation already capitalises substantial pipeline success. Our stance is constructive on the business and neutral to cautiously positive on the equity. The key swing factors over the next 12 months are the US litigation outcome, the pace of Keytruda SC conversion outside the enjoined European markets, and conversion of the Novartis options into named programmes. Investors should size positions for continued event-driven volatility.
It is not investment advice.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Age (disclosed) | Compensation (latest disclosed) |
|---|---|---|---|---|---|
Dr. Park Soon-jae (박순재) | Founder, Chairman, Inside Director, Board Chair; largest shareholder | Co-founded 2008; CEO about 2010/11 to 26 December 2025 | PhD in Biochemistry, Purdue; MIT postdoc; LG Life Sciences; Hanwha Petrochemical; chaired a pharmaceutical company in 2009–10 | Born 22 December 1954 (71) | Not among the top-5 earners in H1 2025 (Smart Today). Full proxy-style figures not disclosed. |
Dr. Tae-Yon Chun (전태연) | President & CEO, Inside Director | Joined September 2020 as EVP (Business Development and IR); CEO since 26 December 2025 | PhD in Biochemistry, University of Wisconsin; JD, Indiana University; US patent attorney; led the ALT-B4 licensing deals | Born 1965 (about 61) | H1 2025: KRW 1.862bn total (KRW 100.5m salary plus KRW 1.761bn from stock-option exercises). Held 7,200 shares (0.01%) in December 2025. |
Kim Hang-yeon (김항연) | EVP & CFO, Inside Director | — | — | Born 1965 (per statbase) | — |
Dr. Vivek Shenoy | Chief Business Development Officer | — | — | — | — |
Dr. Kyuwan Kim | SVP, Head of New Drug Development | — | — | — | — |
Kang Sang-woo | SVP, Management Support | — | — | — | — |
Dr. Ji Hee-jung (지희정) | CEO, Alteogen Biologics | Since about December 2020 (co-CEO of Altos at formation) | PhD in Biochemistry, Purdue; LG Chem; Green Cross; President of Genexine's research institute | — | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake | Source / date |
|---|---|---|
Park Soon-jae (personal) | About 19.07–19.1% (10.21m shares, pre-bonus) | H1 2025 report; FY2025 business report; Hankyung, March 2026 |
Park Soon-jae and related parties | 20.33% | Daishin, May 2026 |
Hyung In-woo (Smart & Growth) and related parties | 5.08% (Hyung personally about 5.05%) | Daishin, May 2026; Hankyung, March 2026 |
Chung Hye-shin (co-founder) | 0.8% (June 2024), after selling 1.6m shares in March 2024 | Wikipedia / Hankyung |
Park Su-min | 0.5% (June 2024) | Wikipedia |
Minority shareholders | 70.05% (247,613 holders) | FY2025 business report (via etfshopping) |
Foreign ownership | About 13.8–14.4% | KRX data, January 2026 |
SkyAlt (National Growth Fund / Skylake vehicle) | KRW 100bn CPS plus KRW 100bn RCPS (being issued October 2026) | Dailypharm / Seoul Economic Daily, October 2026 |
Competitive Landscape
Competitors by Segment
| Business line | Competitor | Offering | Relative positioning |
|---|---|---|---|
SC conversion enzyme platform | Halozyme Therapeutics (US) | ENHANZE® (rHuPH20); MDASE™ patents; Hypercon™ (Elektrofi, acquired November 2025); Surf Bio (acquired December 2025) | Incumbent leader with about 10 approved partnered products (Darzalex SC, Phesgo, Vyvgart Hytrulo and others). Litigation adversary. |
SC conversion (device / formulation alternatives) | Enable Injections (enFuse® on-body delivery) | Large-volume wearable SC delivery | Complementary or substitute for some molecules |
SC conversion (formulation) | Xeris Biopharma (XeriJect™) | High-concentration non-aqueous formulation | Niche substitute |
SC conversion (in-house) | Big pharma high-concentration formulations (e.g., in-house SC versions without hyaluronidase) | Formulation science | Partners can bypass enzymes for low-volume doses |
Aflibercept biosimilars | Samsung Bioepis (Opuviz), Celltrion (Eydenzelt), Amgen (Pavblu), Biocon/Viatris (Yesafili), Sandoz (Afqlir), Formycon, Alvotech/Teva, Sam Chun Dang (SCD411) | Eylea biosimilars | Crowded. Alteogen is a later entrant with a smaller commercial footprint. |
Trastuzumab biosimilars (China) | Henlius and other Chinese and global biosimilar makers | Herceptin biosimilars | Qilu's Anqutuo is one of several |
Standalone hyaluronidase (Korea) | Animal-derived hyaluronidases (multiple domestic suppliers); Halozyme Hylenex (US) | Dispersion adjunct | Tergase is differentiated on purity and lower ISR (injection-site reaction) |
Korean platform biotechs (capital-market peers) | LigaChem Biosciences (ADC), ABL Bio (Grabody), D&D Pharmatech, Voronoi | Licensing-led platforms | Compete for KOSDAQ biotech capital and licensing attention |
Peer Comparison FY2025
| Metric | Alteogen (FY2025) | Halozyme (FY2025) |
|---|---|---|
Revenue | KRW 215.9bn (about US$157m) | US$1,396.6m |
Revenue growth YoY | +109.9% | +38% |
Royalty revenue | Small (Anqutuo; Keytruda SC still in the milestone phase) | US$868m (+52%) |
Operating margin | 49.5% | EBITDA US$657.6m, about 47% of revenue) |
Net margin | 66.8% | 22.7% (net income US$316.9m) |
R&D intensity | Not disclosed (FY) | — |
2026 guidance | None published | Revenue US$1.71–1.81bn; royalties US$1.13–1.17bn |



